Zobrazeno 1 - 10
of 63
pro vyhledávání: '"John, Harlan"'
Autor:
Maria A. Argiriadi, Kangwen Deng, David Egan, Lei Gao, Farid Gizatullin, John Harlan, Denise Karaoglu Hanzatian, Wei Qiu, Ruth Villanueva, Andrew Goodearl
Publikováno v:
Frontiers in Drug Discovery, Vol 2 (2023)
LRP8 is a member of the LDLR-like protein family. It is a transport receptor, which can be used in the design of antibodies specific for investigating increasing exposure to therapeutics with respect to the blood brain barrier (BBB). In this study, a
Externí odkaz:
https://doaj.org/article/7cf38b5884c6403890eae361615c7e1f
Autor:
Maria A. Argiriadi, Lorenzo Benatuil, Ievgeniia Dubrovska, David A. Egan, Lei Gao, Amy Greischar, Jennifer Hardman, John Harlan, Ramesh B. Iyer, Russell A. Judge, Marc Lake, Denise C. Perron, Ramkrishna Sadhukhan, Bernhard Sielaff, Silvino Sousa, Rui Wang, Bradford L. McRae
Publikováno v:
BMC Molecular and Cell Biology, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of
Externí odkaz:
https://doaj.org/article/66a26e4226064b91872d1401b83f9517
Autor:
Jun Guo, Yu Xiao, Ramesh Iyer, Xin Lu, Marc Lake, Uri Ladror, John Harlan, Tanushree Samanta, Medha Tomlinson, Gail Bukofzer, Cherrie Donawho, Alex Shoemaker, Tzu-Hsuan Huang
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0219829 (2019)
Type 1 IFNs stimulate secretion of IP-10 (CXCL10) which is a critical chemokine to recruit effector T cells to the tumor microenvironment and IP-10 knockout mice exhibit a phenotype with compromised effector T cell generation and trafficking. Type 1
Externí odkaz:
https://doaj.org/article/704be8f1301e4ff9a3b08f374f073038
Autor:
Debra T. Chao, Diane Hollenbaugh, Patricia Culp, Alan F. Wahl, Yuni Fang, Catherine Zhang, John Harlan, Danying Song, Marc Lake, Jean Cabel, Ramesh Iyer, Han Kim, Yoshiko Akamatsu, Mien Sho, Siu Sze Tan, Donghee Choi, Nicole A. Belmar, Diane Cohen, Shiming Ye
PC3 cells stably expressing different levels of MSLN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fe02840c673483123e5f0929841c42
https://doi.org/10.1158/2326-6066.22542501.v1
https://doi.org/10.1158/2326-6066.22542501.v1
Autor:
Debra T. Chao, Diane Hollenbaugh, Patricia Culp, Alan F. Wahl, Yuni Fang, Catherine Zhang, John Harlan, Danying Song, Marc Lake, Jean Cabel, Ramesh Iyer, Han Kim, Yoshiko Akamatsu, Mien Sho, Siu Sze Tan, Donghee Choi, Nicole A. Belmar, Diane Cohen, Shiming Ye
Binding affinity of LB-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba6cdbda7ccf3457705f52ec15cef87
https://doi.org/10.1158/2326-6066.22542498
https://doi.org/10.1158/2326-6066.22542498
Autor:
Debra T. Chao, Diane Hollenbaugh, Patricia Culp, Alan F. Wahl, Yuni Fang, Catherine Zhang, John Harlan, Danying Song, Marc Lake, Jean Cabel, Ramesh Iyer, Han Kim, Yoshiko Akamatsu, Mien Sho, Siu Sze Tan, Donghee Choi, Nicole A. Belmar, Diane Cohen, Shiming Ye
Agonistic CD40 monoclonal antibodies (mAb) have demonstrated some clinical activity, but with dose-limiting toxicity. To reduce systemic toxicity, we developed a bispecific molecule that was maximally active in the presence of a tumor antigen and had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694bf4988a8ed4f7c7f07adbc8095610
https://doi.org/10.1158/2326-6066.c.6549954.v1
https://doi.org/10.1158/2326-6066.c.6549954.v1
Autor:
Manoj Menon, Anna Coghill, Innocent Mutyaba, Fred Okuku, Warren Phipps, John Harlan, Jackson Orem, Corey Casper
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191967 (2018)
INTRODUCTION:Cancer treatment options in sub-Saharan Africa are scarce despite an increasing burden of disease. Identification of those cancer patients who would benefit most from the limited resources available would allow broader and more effective
Externí odkaz:
https://doaj.org/article/1f2b5463b514490da098cd8021b2dd2d
Autor:
Catherine Zhang, Yoshiko Akamatsu, Alan F. Wahl, Han Kim, Ramesh Iyer, Jeanne M Cabel, Mien Sho, Nicole A. Belmar, Shiming Ye, Patricia Culp, Debra Chao, Marc R. Lake, Siu sze Tan, Cohen Diane Sau Mun, Yuni Fang, Diane Hollenbaugh, Danying Song, Donghee Choi, John Harlan
Publikováno v:
Cancer Immunology Research. 7:1864-1875
Agonistic CD40 monoclonal antibodies (mAb) have demonstrated some clinical activity, but with dose-limiting toxicity. To reduce systemic toxicity, we developed a bispecific molecule that was maximally active in the presence of a tumor antigen and had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ec3a582b90c7996eb5c7dbafda81db
https://doi.org/10.1158/2326-6066.cir-18-0805
https://doi.org/10.1158/2326-6066.cir-18-0805